Role of Cleaning-in-Place in the Purification of mAb Supernatants Using Continuous Cation Exchange Chromatography

Abstract Monoclonal antibodies (mAbs) are among the most important therapeutic proteins for the treatment of cancer. They also find wide application in the field of diagnostics. The market for mAbs was US$ 5.4 billion in 2002 and is expected to triple by 2010 (1). MAbs are mainly produced in cell culture and purified by chromatography. Apart from the mAb, the downstream processing is confronted with a multitude of impurities from the upstream process. Some of these impurities bind strongly to the chromatographic stationary phase and can only be removed by separate cleaning solutions. Depending on the type of media used, e.g. affinity or ion exchange, differing cleaning regimes may have to be applied. In addition, sanitization is required to prevent microbial contamination. Both steps are closely tied to the mAb production step and need to be repeated in regular intervals. In this work, the impact of irreversible impurity adsorption on the separation performance is investigated experimentally; first for a batch column and then for a continuous chromatographic process. At first, the retention time of a model substance is established as a suitable measure to describe the degree of irreversible adsorption. The impact of the presence and the absence of cleaning-in-place (CIP) on the retention time of the model substance is demonstrated. Since the issue of column cleaning is particularly important if processes are operated in continuous mode, in the second part of this work the introduction of a CIP step in the continuous multicolumn countercurrent solvent gradient purification (MCSGP) process is investigated. The process purifies a mAb from a cell culture supernatant that also contains irreversibly adsorbing impurities—or impurities that desorb in a later cycle of the process as a contamination. Following the same approach as for the batch experiments, the MCSGP process is operated in the presence and the absence of CIP in order to track prospective changes of the process performance caused by changes in the product retention time. Instead of the model substance, a cell culture supernatant, providing a real case impurity profile in an industrial application is used for the process. Although an impact of the product retention time change on the process yield is not observed it is shown that CIP is required for a stable long-term operation in terms of purity and system pressure drop. With the introduction of a CIP step the process was successfully operated for 9000 min (6 days) without interruption.

[1]  Massimo Morbidelli,et al.  Chromatographic separation of three monoclonal antibody variants using multicolumn countercurrent solvent gradient purification (MCSGP) , 2008, Biotechnology and Bioengineering.

[2]  E. Boschetti,et al.  Composite affinity sorbents and their cleaning in place. , 1990, Journal of chromatography.

[3]  Cordin Arpagaus,et al.  Two-fraction and three-fraction continuous simulated moving bed separation of nucleosides. , 2004, Journal of chromatography. A.

[4]  Massimo Morbidelli,et al.  A semicontinuous 3-column countercurrent solvent gradient purification (MCSGP) process. , 2008, Biotechnology and bioengineering.

[5]  Massimo Morbidelli,et al.  SMB Operation for Three-Fraction Separations: Purification of Plasmid DNA , 2005 .

[6]  Massimo Morbidelli,et al.  A continuous multicolumn countercurrent solvent gradient purification (MCSGP) process , 2007, Biotechnology and bioengineering.

[7]  U. Rinas,et al.  Purification of recombinant human basic fibroblast growth factor: stability of selective sorbents under cleaning in place conditions. , 1995, Journal of chromatography. A.

[8]  A. Staby,et al.  Comparison of loading capacities of various proteins and peptides in culture medium and in pure state. , 1998, Journal of chromatography. A.

[9]  P. Levison,et al.  Validation studies in the regeneration of ion-exchange celluloses , 1995 .

[10]  M. Frech,et al.  Scale-Up of Antibody Purification , 2004 .

[11]  Leonard Steinborn The United States Food and Drug Administration and ICH Guidance for Industry Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients , 2004 .

[12]  Gary Walsh,et al.  Biopharmaceuticals: recent approvals and likely directions. , 2005, Trends in biotechnology.

[13]  G. Hale,et al.  Repeated cleaning of protein A affinity column with sodium hydroxide. , 1994, Journal of immunological methods.

[14]  Nigel J. Titchener-Hooker,et al.  Effect of fouling on the capacity and breakthrough characteristics of a packed bed ion exchange chromatography column , 2006, Bioprocess and biosystems engineering.